Ontology highlight
ABSTRACT:
SUBMITTER: Wu TJ
PROVIDER: S-EPMC4761412 | biostudies-literature | 2015 Apr
REPOSITORIES: biostudies-literature
Wu Tzung-Ju TJ Wang Xiaowen X Zhang Yanjie Y Meng Linghua L Kerrigan John E JE Burley Stephen K SK Zheng X F Steven XF
Cell reports 20150409 3
Protein kinases are therapeutic targets for human cancer. However, "gatekeeper" mutations in tyrosine kinases cause acquired clinical resistance, limiting long-term treatment benefits. mTOR is a key cancer driver and drug target. Numerous small-molecule mTOR kinase inhibitors have been developed, with some already in human clinical trials. Given our clinical experience with targeted therapeutics, acquired drug resistance in mTOR is thought likely, but not yet documented. Herein, we describe iden ...[more]